A Strategic Move in Oncology
Johnson & Johnson is spending just over $3 billion in cash to purchase Halda Therapeutics, aiming to strengthen its oncology portfolio with a slate of oral solid tumor treatments.
Through the deal, J&J will pick up Halda’s pipeline of oral cancer therapies, according to Monday’s announcement. The centerpiece is HLD-0915, a once-daily prostate cancer drug that received the FDA fast track status in August.
Promising Clinical Results
Phase I/II results released in late 2024 showed promising early anti-tumor activity, including reductions in prostate cancer biomarkers and partial responses in all five evaluable patients. Halda is continuing to run its Phase I/II study in metastatic, castration-resistant prostate cancer (mCRPC).
Jennifer Taubert, EVP of Innovative Medicine at J&J, said in a statement that the acquisition bolsters the company’s already robust cancer portfolio by adding a promising prostate cancer program and a platform that could be applied to multiple cancers and other diseases, creating potential drivers of growth over the medium and long term.
Future Growth and Ambitions
During a second-quarter earnings call in July, CEO Joaquin Duato set an ambitious goal for Johnson & Johnson: to generate $50 billion in oncology sales by 2030.
Innovative RIPTAC Platform
Contributing to that ambition, Halda brings a discovery platform known as Regulated Induced Proximity Targeting Chimera (RIPTAC). Using this approach, the company designs paired ligands that bind two different proteins at once – one found mainly on tumor cells and another that performs an essential cellular function. By bringing these together, the drugs are intended to selectively kill cancer cells while minimizing damage to healthy tissue.
Halda classifies all of its candidates as RIPTACs. Beyond HLD-0915 in prostate cancer, its pipeline includes a breast cancer program aimed at hormone receptor–positive (HR+) tumors, a candidate being evaluated in lung cancer and additional early-stage oncology therapies that have not yet been disclosed in detail.
Rapid Payoff for a Young Company
For Halda, the buyout marks a rapid payoff for a relatively young company. Founded in 2019 out of the lab of Yale chemist Craig Crews, Halda quickly attracted investor interest, culminating in a second Series B round of $126 million to advance HLD-0915 and an unnamed breast cancer candidate through development.
J&J’s Broader Strategy
From Johnson & Johnson’s perspective, Halda is its second major acquisition of the year, following the $14.6 billion takeover of neuropsychiatry-focused Intra-Cellular Therapies in January, which is still the largest pharma M&A deal announced so far in 2025. At the time, J&J signaled that the remainder of 2025 would likely be relatively subdued on the business development front.
J&J and Halda expect the acquisition to wrap up in the coming months, pending antitrust approval and the fulfillment of other customary closing conditions, according to the companies’ announcement. Johnson & Johnson added that it plans to share more details on the transaction during its fourth-quarter earnings update in early 2026.
Strategic Implications & Next Steps
The acquisition of Halda not only augments J&J’s pipeline in a meaningful way but also provides a flexible leap-forward platform with RIPTAC technology. This could accelerate J&J’s entry into precision oncology, giving it the capability to tackle tumors once considered difficult to drug.
J&J may now design combination trials leveraging RIPTACs alongside its existing assets, potentially creating novel therapy regimens for prostate, breast, and lung cancer. Furthermore, by integrating Halda’s early-stage programs, J&J can strategically choose which candidates to fast-track depending on unmet need, competitive landscape, and biomarker readine
From a business perspective, the deal helps J&J hedge against risk: while HLD-0915 offers near-term potential via its prostate cancer program, the RIPTAC platform lays the foundation for long-term innovation and optionality. For patients, this could mean access to more precise, less toxic therapies in the next decade
